Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review-Reference-Cited by-同舟云学术

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

Published:2023-09-14 Issue:10 Volume:13 Page:2171-2185
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Girolomoni Giampiero^ORCID,Savage Laura^ORCID,Gisondi Paolo^ORCID,Svensson Åke,Mahé Emmanuel^ORCID,Augustin Matthias,Puig Luis^ORCID

Funder

Biogen

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-01014-x.pdf

Reference92 articles.

1. Pharmacy Times. New Treatment for Plaque Psoriasis Approved in Europe, J. Barrett, Editor. 2018. p. https://www.pharmacytimes.com/view/new-treatment-for-plaque-psoriasis-approved-in-europe.

2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.

3. Griffiths CEM, et al. Psoriasis. Lancet. 2021;397(10281):1301–15.

4. Parisi R, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590.

5. van de Kerkhof PC, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002–10.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis;BMC Immunology;2024-07-04

2. A real-world retrospective study on biologics utilization in patients with psoriasis in Greece during the period 2015–2020;Archives of Dermatological Research;2024-06-07

3. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities;Expert Review of Clinical Pharmacology;2024-04-02

4. Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation;Rheumatology and Immunology Research;2024-03-01